Table 2.
Distribution frequency of MMP-11 genotypes in 578 patients with prostate cancer.
| Variable | Biochemical Recurrence | OR (95% CI) | AOR (95% CI) | |
|---|---|---|---|---|
| No (n = 403) | Yes (n = 175) | |||
| rs131451 | ||||
| TT | 117 (29.0%) | 58 (33.1%) | 1.00 | 1.00 |
| TC | 209 (51.9%) | 91 (52.0%) | 0.878 (0.589–1.310) | 0.727 (0.452–1.170) |
| CC | 77 (19.1%) | 26 (14.9%) | 0.681 (0.395–1.174) | 0.669 (0.348–1.286) |
| TC+CC | 286 (71.0%) | 117 (66.9%) | 0.825 (0.564–1.208) | 0.713 (0.453–1.121) |
| rs738791 | ||||
| CC | 189 (46.9%) | 83 (47.4%) | 1.00 | 1.00 |
| CT | 173 (42.9%) | 81 (46.3%) | 1.066 (0.737–1.542) | 0.905 (0.580–1.412) |
| TT | 41 (10.2%) | 11 (6.3%) | 0.611 (0.299–1.247) | 0.615 (0.270–1.403) |
| CT+TT | 214 (53.1%) | 92 (52.6%) | 0.979 (0.686–1.397) | 0.849 (0.555–1.300) |
| rs2267029 | ||||
| GG | 195 (48.4%) | 97 (55.4%) | 1.00 | 1.00 |
| GA | 179 (44.4%) | 69 (39.4%) | 0.775 (0.536–1.121) | 0.805 (0.518–1.251) |
| AA | 29 (7.2%) | 9 (5.2%) | 0.624 (0.284–1.370) | 0.638 (0.247–1.648) |
| GA+AA | 208 (51.6%) | 78 (44.6%) | 0.754 (0.528–1.077) | 0.782 (0.512–1.196) |
| rs738792 | ||||
| TT | 178 (44.2%) | 85 (48.6%) | 1.00 | 1.00 |
| TC | 186 (46.2%) | 80 (45.7%) | 0.901 (0.623–1.301) | 0.961 (0.619–1.493) |
| CC | 39 (9.7%) | 10 (5.7%) | 0.537 (0.256–1.127) | 0.566 (0.232–1.381) |
| TC+CC | 225 (55.8%) | 90 (51.4%) | 0.838 (0.587–1.195) | 0.893 (0.584–1.366) |
| rs28382575 | ||||
| TT | 377 (93.5%) | 164 (93.7%) | 1.00 | 1.00 |
| TC | 26 (6.5%) | 11 (6.3%) | 0.973 (0.469–2.015) | 1.240 (0.513–2.995) |
| CC | 0 (0%) | 0 (0.0%) | — | — |
| TC+CC | 26 (6.5%) | 11 (6.3%) | 0.973 (0.469–2.015) | 1.240 (0.513–2.995) |
The odds ratios (ORs) and their 95% confidence intervals (CIs) were estimated by logistic regression models. The adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) were estimated by multiple logistic regression models after controlling for age at diagnosis, PSA levels at diagnosis, pathologic Gleason grade group, clinical T stage, pathologic T stage, pathologic N stage, seminal vesicle invasion, perineural invasion, lymphovascular invasion, D’Amico classification, and biochemical recurrence.